BA
ZVRA icon

BlackRock Advisors’s Zevra Therapeutics ZVRA Stock Holding History

BlackRock Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$12K Hold
263
– – ﹤0.01% 3548
2016
Q3 		$19K Buy
263
+239
+996% +$17K ﹤0.01% 3466
2016
Q2 		$2K Hold
24
– – ﹤0.01% 3718
2016
Q1 		$6K Hold
24
– – ﹤0.01% 3653
2015
Q4 		$8K Buy
+24
New +$6.51K ﹤0.01% 3663

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Advisors's ZVRA Position: Q4 2016 in Review

BlackRock Advisors held its Zevra Therapeutics (ZVRA) position steady in Q4 2016 at 263 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

BlackRock Advisors first reported a position in ZVRA in Q4 2015 and has held it in 5 quarters since. The position peaked at $19K in Q3 2016. 36 funds tracked by Wall St. Rank hold ZVRA as of Q4 2016.

  • BlackRock Advisors held 263 shares of Zevra Therapeutics worth $12K as of Q4 2016.
  • BlackRock Advisors left its Zevra Therapeutics share count unchanged in Q4 2016.
  • Zevra Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3548 holding.
  • BlackRock Advisors first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Advisors's Zevra Therapeutics position peaked at $19K in Q3 2016.
  • 36 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.